In February 2024, Bristol Myers Squibb announced a definitive agreement to acquire Mirati Therapeutics, a commercial-stage targeted oncology company specializing in KRAS G12C inhibitors. This USD 4.8 billion acquisition adds the FDA-approved KRAZATI® (adagrasib) to BMS's portfolio, along with promising early-stage assets targeting KRAS and other driver mutations.
In January 2024, BMS and Seagen announced a collaboration to launch a Phase 3 trial evaluating ADCETRIS® in combination with chemotherapy for treatment-naive adult patients with Hodgkin lymphoma. This partnership leverages the strengths of both companies to pursue potentially curative options for this cancer.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5529
Published Date: Jan 12, 2024
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Increasing demand for healthcare sector is the major factor driving the market growth.
The market size of S1P receptor modulator drugs is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2024-2036.
The major players in the market Novartis International AG, Bristol Myers Squibb Company, Johnson & Johnson, Biogen Inc., Merck & Co., Inc., F. Hoffmann-La Roche Ltd, and others.
The hospitals segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the Asia Pacific region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.